Avaliação do uso do óxido nítrico no tratamento da hipertensão pulmonar persistente do recém-nascido: uma metanálise by Oliveira, Carlos Augusto Cardim de et al.

REV. HOSP. CLÍN. FAC. MED. S. PAULO 55(4):145-154, 2000JULY-AUGUST
From the Department of Pediatrics, Hospital
das Clínicas, Faculty of Medicine, University
of São Paulo.
REVIEW
INHALED NITRIC OXIDE IN THE MANAGEMENT OF
PERSISTENT PULMONARY HYPERTENSION OF THE
NEWBORN: A META-ANALYSIS
Carlos Augusto Cardim de Oliveira, Eduardo J Troster and Crésio R Pereira
RHCFAP/3017
OLIVEIRA CAC et al. - Inhaled nitric oxide in the management of persistent pulmonary hypertension of the newborn: a meta-
analysis. Rev. Hosp. Clín. Fac. Med. S. Paulo 55 (4):145-154, 2000.
Objectives: To evaluate the use of inhaled nitric oxide (NO) in the management of persistent pulmonary hypertension of the
newborn. Methods: Computerized bibliographic search on MEDLINE, CURRENT CONTENTS and LILACS covering the period
from January 1990 to March 1998; review of references of all papers found on the subject. Only randomized clinical  trials evaluating
nitric oxide and conventional treatment were included. Outcomes studied: death, requirement for extracorporeal membrane
oxygenation (ECMO), systemic oxygenation, complications at the central nervous system and development of chronic pulmonary
disease. The methodologic quality of the studies was evaluated by a quality score system, on a scale of 13 points. Results: For
infants without congenital diaphragmatic hernia, inhaled NO did not change mortality (typical odds ratio: 1.04; 95% CI: 0.6 to
1.8); the need for ECMO was reduced (relative risk: 0.73; 95% CI: 0.60 to 0.90), and the oxygenation was improved (PaO2 by a
mean of 53.3 mm Hg; 95% CI: 44.8 to 61.4; oxygenation index by a mean of -12.2; 95% CI: -14.1 to -9.9). For infants with
congenital diaphragmatic hernia, mortality, requirement for ECMO, and oxygenation were not changed. For all infants, central
nervous system complications and incidence of chronic pulmonary disease did not change. Conclusions: Inhaled NO improves
oxygenation and reduces requirement for ECMO only in newborns with persistent pulmonary hypertension who do not have
diaphragmatic hernia. The risk of complications of the central nervous system and chronic pulmonary disease were not affected by
inhaled NO.
DESCRIPTORS: Nitric oxide.  Newborn.  Pulmonary hypertension.  Extracorporeal membrane oxygenation (ECMO).
Meta-analysis.
At birth, a disturbance of oxygen-
ation leads to persistence of elevated
pressure of the pulmonary circulation.
Some arteries do not have a complete
vasodilation, and others remain closed.
Gersony1 described and named this
syndrome persistence of fetal circula-
tion.
Persistent pulmonary hypertension
of the newborn (PPHN) is the common
final pathway of pathologic conditions
of circulatory and respiratory systems,
including: respiratory distress syn-
drome, pneumonia with or without
sepsis, pulmonary hypoplasia associ-
ated with congenital diaphragmatic
hernia and cardiac malformations. The
increased vascular tone of pulmonary
circulation persists even after the pre-
cipitating insult is removed. A higher
pressure of the pulmonary artery leads
to right-to-left shunting at the ductus
arteriosus and/or foramen ovale, result-
ing in hypoxemia. Pulmonary paren-
chymal disease intensifies the uneven
ventilation-perfusion ratio, which
worsens the hypoxemia, increasing va-
sospasm2-11.
The true incidence of PPHN is un-
known because of non-uniform diag-
nostic criteria and the lack of system-
atic population-based studies. The de-
scribed ratio ranges from 1 in 500 to 1
in 1400 live births, and morbidity is
expressive, including neurological defi-
cits and chronic pulmonary disease.
PPHN is one of the most serious ill-
nesses in newborn intensive care
units3,11-14.
The conventional treatment of
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PPHN includes: optimized ventilation
with high fractions of inspired oxygen,
induced respiratory and metabolic al-
kalosis, systemic vasodilators, hemo-
dynamic support, correction of meta-
bolic disorders, and the maintenance of
a quiet environment15-20.
Nitric oxide is a free amphiphilic
radical that acts as an intracellular and
intercellular messenger, increasing the
levels of c-GMP, which reduces the in-
tracellular concentration of calcium,
inducing vasodilation21,22.
Although the infusion of vasodila-
tor agents has been shown to decrease
pulmonary vascular resistance, its use
is limited because of a concomitant de-
crease in systemic vascular tone, wors-
ening the intrapulmonary shunt. The
high affinity of NO to ferrous ion heme
proteins results in its rapid inactivation
by blood hemoglobin, giving to in-
haled NO the property of selectivity to
the pulmonary vascular bed22-27.
Clinical evidence has demonstrated
that inhaled NO improves oxygenation
in PPHN, but until now, trials have
been too small to give reliable answers.
The outcomes measured are not mean-
ingful regarding mortality or quality of
life, but rather are meaningful regard-
ing surrogate outcomes like oxygen-
ation14,28.
The objective of this review was to
estimate more precisely the effects of
inhaled NO in the management of
PPHN.
METHODS
Study Identification:  All clinical
trials concerning NO and PPHN pub-
lished from January 1990 to March
1998 were retrieved. This pool of stud-
ies was identified by cross-referencing
the following medical subject heading
terms using MEDLINE, CURRENT
CONTENTS and LILACS: nitric oxide
and infant; nitric oxide and newborn;
nitric oxide and pulmonary hyperten-
sion; pulmonary hypertension and in-
fant; pulmonary hypertension and new-
born. In addition, we reviewed manu-
ally the reference lists of each re-
trieved article obtained from the elec-
tronic databases, from other non-sys-
tematic reviews, and from congress
chronicles. Only randomized clinical
trials published in English, French,
Spanish, and Portuguese were se-
lected. We excluded incomplete stud-
ies and those from the same authors
with the same population.
Study Population: Term (>37
weeks of gestational age), or near term
(>34< 37 weeks of gestational age)
newborns (< 28 days of age at the be-
ginning of the study) with hypoxemia
and diagnosis of PPHN done by
echocardiography were studied. Infants
with intracardiac shunting due to struc-
tural heart disease (except ductus arte-
riosus) were excluded.
Interventions: The treated group
received administration of inhaled NO
by tracheal cannula. The control group
was managed with conventional treat-
ment.
Outcomes: Death, requirement for
ECMO, systemic oxygenation, distur-
bances of the central nervous system
(hemorragic disorders and convul-
sions), and development of chronic
pulmonary disease during hospitaliza-
tion were the outcomes studied.
Assessment of methodologic
quality: The quality pattern of each
study was assessed according to the
Heyland score system30, with a maxi-
mum of 13 points.
Data analysis: Using the REVIEW
MANAGER software, version 3.1, The
Cochrane Collaboration, March 1998,
data were combined to estimate, for
categorical outcomes, the typical odds
ratio, relative risk, relative risk reduc-
tion, absolute risk redution and num-
ber needed to treat. Outcomes were
measured on a continuous scale, and
typical estimates for weighted mean
difference were calculated, as well as
their correspondent 95% confidence in-
tervals. The heterogeneity of treatment
effects across the studies was ascer-
tained by a chi-square analysis, using
the null hypothesis that results were
similar, where p>0.05 for the test of
homogeneity is consistent with the as-
sumption that differences in study re-
sults are due to chance. Relative risk,
and not odds ratio, was calculated if the
outcome rate measured was higher
than 0.2.
RESULTS
Study selection: From January
1990 to March 1998, 261 publications
were found that dealt with NO and
PPHN. Eight randomized clinical trials
fulfilled the inclusion criteria. The
characteristics of these studies are de-
scribed in Table 1.
The meta-analysis of results for in-
fants without congenital diaphragmatic
hernia included seven studies (548
newborns). Only two trials were se-
lected for meta-analysis for infants
with congenital diaphragmatic hernia
(70 newborns).
Validity criteria and quality score of
selected clinical trials are listed in
Table 2.
The tests for homogeneity were
non-significant, meaning homoge-
neous results in all analyses, except for
“oxygenation index at 30 min”.
PPHN without congenital diaphrag-
matic hernia
A) Death during hospitalization.
The meta-analysis included 5 studies
(513 newborns) 30,32,34,36,37. There were
31 (11%) deaths in the NO group, and
26 (12%) in the control group. There
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Table 1 - Characteristics of selected clinical trials.
Authors/year Multicentric Study Gestational Hypoxemia and Co-interventions:
(reference) Population age(weeks) Mechanical Ventilation Surfactant and/or
HFOV a
Barefield 30 No 17 b >35 Yes Not Accepted
Cornfield 31 Yes 23 Mean:37,3 c Yes Not Accepted
Davidson 32 Yes 155 >37 Yes Not Accepted
Day 33 No 22      -c Yes Accepted
NINOS 34 Yes 235 >34 Yes Accepted
NINOS 35 Yes 53 d >34 Yes Accepted
Roberts 36 Yes 58 >37 Yes Accepted
Wessel 37 Yes 49 >34 Yes Accepted
a  High frequency oscillatory ventilation
b  Population studied 24, but only 17 were randomized
c  Minimal gestational age not mentioned
d Study interrupted because of suggestion of worse outcome
Table 2 - Methodologic quality assessment of eight selected trialsa .
 Author/yr Barefield Cornfield Davidson Day NINOS NINOS Roberts Wessel
(reference) 1996 30 1997 31 1998 32 1998 33 1997 34 1997 35 1997 36 1997 37
Randomization 2 2 2 2 2 2 2 2
Blinding 1 1 1 1 1 1 1 0
Analysis 2 2 2 2 2 2 2 2
Patient selection 1 1 1 1 1 1 1 1
Comparability of 1 1 1 0 1 1 1 1
groups at baseline
Extent of follow-up 1 1 1 1 1 1 1 1
Treatment protocol 1 1 1 1 1 1 1 1
Co-interventions 1 1 1 1 1 1 1 1
Crossovers 2 1 1 2 2 1 2 2
TOTAL 12 11 11 11 12 11 12 11
a
 Score system according to Heyland29.
was no difference in mortality between
groups (odds ratio: 1.04; 95% CI: 0.59
to 1.82) (Table 3; Fig. 1).
B) Requirements for extracorpo-
real membrane oxygenation
(ECMO). Five studies 30-32,34,36,37 were
selected, including 537 newborns.
Fewer patients from the NO group
needed ECMO, 101/305 (33%), com-
pared to 115/232 (50%) controls (rela-
tive risk: 0.73; 95% CI: 0.6 to 0.9)
(Table 4 and Fig. 2).
C) Systemic oxygenation. This
outcome was analyzed in 7 trials30-
34,36,37
, but the unity of measures was
not always the same. In all the studies
except one 32, it was concluded that NO
improved oxygenation. The meta-
analysis data was consistent with the
analyzed measurement. The weighted
mean differences showed better results
for the oxygenation index and PaO2 for
those treated with NO (Table 5; Fig. 3).
D) Disturbances of the central
nervous system. Three studies 32,34,37
were selected, with 420 newborns.
There was no difference between NO-
treated and control groups (odds ratio:
0.83; 95% CI: 0.50 to 1.37) (Table 6;
Fig. 4).
E) Development of chronic pul-
monary disease during hospitaliza-
tion. This meta-analysis included 2
trials32,34 totaling 378 infants. There
was no difference between groups for
this outcome. Forty-six cases of
chronic pulmonary disease were found,
30/217 (11%) in the NO-treated group,
and 17/161 (14%) in the control group
(odds ratio: 1.3; 95% CI: 0.69 to 2.46)
(Table 7, Fig. 5).
PPHN with congenital diaphrag-
matic hernia
A) Death or ECMO requirement:
These outcomes were analyzed in only
one trial35, and both were considered as
a single outcome. From the 53 patients
studied, 28 were in the control group
and 25 were in the NO-treated group.
The rate for the control group was 0.82
and for those treated with NO was 0.96
(relative risk: 1.17; 35% CI: 0.97 to
1.41) (Table 8).
B) Systemic oxygenation: Two tri-
als 33,35 were selected, but the authors
have published their data differently, so
we could not assemble them in a
unique meta-analysis. In one trial 35, a
subgroup of 10 patients with pulmo-
nary hypoplasia did not have an im-
provement of oxygenation when com-
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Table 3 - Nitric oxide vs Conventional treatment: Death during hospitalization.
Results (%) 95% Confidence interval
Control group 0.12 (12) -
NO group 0.11 (11) -
Relative risk 1.03 0.62 to 1.72
Odds ratio 1.04 0.59 to 1.82
Figure 1 - Nitric oxide vs conventional treatement: death during hospitalization.
Figure 2 - Nitric oxide vs conventional treatement: requirement for ECMO during hospitalization.
Table 4 - Nitric oxide vs Conventional treatment: Requirement for ECMO during
hospitalization.
Results (%) 95% Confidence interval
Control group 0.50 (50) -
NO group 0.33 (33) -
Relative risk 0.73 0.60 to 0.90 *
Absolute risk reduction 0.13 (13) 0.05 to 0.21
Relative risk reduction 0.26 (26) 0.10 to 0.40
Number needed to treat 8 4.74 to 22.22
* P < 0.05
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Table 5 - Measurements of systemic oxygenation of the seven selected studies.
Study Population Results
(95% confidence interval)
PaO2 (torr) at 30 and 60 min Control group: 53 WMD b: 53.18 (44.8 a 61.4)
NO group: 57
OI c at 30 and 60  min Control: 94 WMD: -12.17 (-14.4 a –9.9)
NO group: 171
Number of improved cases Control group: 28 RR d: 7.47 (1.9 a 29.6)
at 30 and 60 min NO group: 30 OR e: 8.34 (2.8 a 25.1)
ARR f: -0.46 (-0.6 a –0.2)
RRR g: -6.47 (-28.6 a –0.9)
NNT h: -2.16 (-3.8 a –1.5)
PaO2 variation at 30 and 60min Control group: 121 WMD: 48.50 (30.3 a 66.6)
NO group: 114
OI c variation at 30 and 60 min Control group: 121 WMD: -14.90 (-20.3 a –9.5)
NO group: 114
OI c reduction after end of treatment Control group: 13 WMD: -9.50 (-11.51 a –7.49)
NO group: 13
a) Partial pressure of arterial oxygen; b) weighted mean difference; c) oxygenation index; d) relative
risk; e) odds ratio; f) absolute risk reduction; g) relative risk reduction; h) number needed to treat.
Figure 3 - Nitric oxide vs conventional treatement: systemic oxygenation.
pared with the control group; but con-
sidering only the NO-treated group, the
measurements were better after treat-
ment in comparison with the baseline
(PaO2: 29 ±± 3 mm Hg vs 45 ±± 10
mm Hg; P<0.05). In the larger trial37,
the authors did not find an improve-
ment for this outcome (Table 9).
C) Disturbances of the central
nervous system: The only study
found37 showed no difference between
the groups: 4/28 (14%) events in con-
trol group and 4/25 (16%) in NO-
treated group (odds ratio: 1.14; 95%
CI: 0.26 to 5.07)
D) Development of chronic pul-
monary disease: The same trial37 was
again the only one to study this end-
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Table 6 - Nitric oxide and Conventional treatment: disturbances of the central
nervous system.
Results (%) 95% Confidence interval
Control group 0.20 (20) -
NO group 0.19 (19) -
Odds ratio 0.83 0.50 to 1.37
Table 7 - Nitric oxide vs Conventional treatment: Development of chronic
pulmonary disease during hospitalization.
Results (%) 95% Confidence interval
Control group 0.11 (11) -
NO group 0.14 (14) -
Relative risk 1.26 0.72 to 2.24
Odds ratio 1.30 0.69 to 2.46
Absolute risk reduction 0.02 (2) -0.97 to 0.04
Relative risk reduction 0.27 (27) -1.24 to 0.28
Number needed to treat Not significant -
Figure 4 - Nitric oxide vs conventional treatement: disturbances of the central nervous system.
Figure 5 - Nitric oxide vs conventional treatement: development of chronic pulmonary disease during hospitalization.
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Table 8 - PPHN with congenital diaphragmatic hernia: Death or ECMO
requirement.
Results (%) 95% Confidence interval
Control group 0.82 (82) -
NO group 0.96 (96) -
Relative risk 1.17 0.97 to 1.41
Absolute risk reduction 0.14 (14) -0.02 to 0.30
Relative risk reduction 0.17 (17) 0.03 to 0.41
Number needed to treat 7.19 3.33 to 43.48
Table 9 - PPHN with congenital diaphragmatic hernia: Systemic oxygenation.
Increase in PaO2 torr Decrease in oxygen index
NO groupª 7.80 (+ 19.80) -2.70 (+ 23.40)
Control groupª 1.10 (+ 7.60) 4.00 (+ 14.80)
P value 0.22 0.27
WMD b (95% confidence interval) 6.70 (-1.55 to 14.95) -6.70 (-17.38 to 3.98)
ª Media (+standard deviation)
b
 Weighed mean difference
point, and no benefit was demonstrated
with inhaled NO (relative risk: 0.62;
95% CI: 0.24 to 1.61).
DISCUSSION
Infants without congenital diaphrag-
matic hernia
For the majority of intensive care
unit trials, mortality is the most mean-
ingful outcome because it is easily
measured and clinically important38.
The results of this meta-analysis,
involving 531 patients without dia-
phragmatic hernia, may appear to ex-
clude any possible benefit from inhaled
NO in reducing the mortality of infants
with persistent pulmonary hyperten-
sion.
However the lower bound of the
95% confidence interval—the one
which suggests the largest benefit from
treatment—was 0.59, showing that
clinically important benefits fall within
the confidence interval, so the trial can-
not definitely rule out the possibility
that the treatment is beneficial for this
outcome. Furthermore, although a
population of 531 patients may seem
expressive, the power of this meta-
analysis would be nearest 30% (Type
II error: 0.7) if the expected reduction
in death rate with the use of NO was
30%. This means that there would be
a 70% chance that we wrongly ac-
cepted the null hypothesis and that we
could not have detected the effect of
inhaled NO on mortality, even if it may
exist. The power would be greater if
the baseline mortality was higher or if
the sample was larger.
Therefore, it would be premature to
definitely rule out inhaled NO from the
management resources for PPHN be-
cause we have not found a reduction in
mortality. In doing so, we might be
giving up a “gray zone” intervention
with great potential benefits38,39.
Mechanisms for suboptimal inhaled
NO responses are: unsuspected struc-
tural heart disease; left ventricular dys-
function, decreased lung volume in as-
sociation with pulmonary parenchymal
disease, pulmonary edema, low con-
centrations of NO for the severity of
the disease, paradoxical response to
NO, worsening of the ventilation/per-
fusion ratio, cytotoxicity of NO and its
metabolites, structural abnormalities of
the pulmonary vascular tree, undiag-
nosed alveolar capillary dysplasia or
pulmonary hypoplasia, non-optimized
hemodynamic and ventilatory support,
and undetected biochemical abnormali-
ties23,31,32,36,37,40,42,43.
If we estimate mortality in the con-
trol group as 12%, this means that 88%
of the infants would survive. Therefore
direct measures of quality of life have
also clinically meaningful outcomes. In
the same way, a lower requirement for
invasive, potentially harmful, and ex-
pensive therapeutic procedures such as
ECMO is also beneficial44;45.
Systemic arterial oxygenation im-
proved with NO treatment. Although
physiologically relevant, to be consid-
ered a valid outcome, this response
should correlate to a true clinical out-
come and fully capture the treatment
effect.
The pathophysiologic mechanisms
of PPHN associated with CDH and the
pharmacological actions of inhaled NO
help to explain the reasons for the poor
responses of these infants. In some pa-
tients, there was temporary improve-
ment of systemic oxygenation, but
even this positive result was not signifi-
cant.
Implications for Clinical Practice
Inhaled NO appears to improve the
outcome in hypoxemic-term and near-
term infants with PPHN. We do not
consider it as the “magic bullet”, but
rather as a part of a strategy address-
ing the complex cardiopulmonary in-
teractions that characterize this syn-
drome. One of the possible co-inter-
ventions is a rescue treatment with high
frequency ventilation and/or exogenous
surfactant, allowing the NO to contact
most pulmonary areas, improving the
ventilation/perfusion rate. Adjunctive
therapy of hemodynamic support is
also useful in the maintenance of sys-
temic arterial pressure, an essential
condition to change the right to left in-
tracardiac shunting. Patients selected
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for inhaled NO treatment cannot have
high degrees of structural pulmonary
abnormalities (hypoplasia or alveolar
capillary dysplasia) that could prevent
the action of the gas. An adequate con-
centration of inhaled NO (probably be-
tween 5 and 20 ppm) must be used to
achieve the best response in each clini-
cal situation and to prevent the cyto-
toxic effects. The treatment must be
initiated before structural pulmonary
changes have developed40-43.
More clinical trials considering the
above mentioned considerations must
be performed.
With concentrations from 5 to 20
ppm, the potential toxic effects includ-
ing methemoglobinemia and lung in-
jury caused by NO2 , peroxynitrite, and
hydroxyl radical formation are mini-
mal. Inhalation therapy with NO is less
costly than ECMO; the cost for treat-
ing 3 patients with ECMO is equiva-
lent to the costs of the system to de-
liver NO to several more patients.
In congenital diaphragmatic hernia,
NO remains an unproved treatment.
For these infants, when ECMO crite-
ria are fulfilled, time must not be
wasted with therapeutic treatments
with NO that could postpone ECMO.
Inhaled NO may be effective in neo-
nates with hypoplastic lungs who need
to be transported to an ECMO center.
Some infants seem to have a better re-
sponse when NO was used after a pe-
riod with ECMO or in cases that de-
veloped postoperative pulmonary hy-
pertension44,45.
CONCLUSIONS
In the management of persistent
pulmonary hypotension (PPHN) of
term and near-term newborns without
congenital diaphragmatic hernia
(CDH) or pulmonary hypoplasia, in-
haled nitric oxide (NO) reduces re-
quirements for extracorporeal mem-
brane oxygenation (ECMO) and im-
proves systemic oxygenation, but does
not change mortality.
For infants with CDH or pulmo-
nary hypoplasia, there were no differ-
ences between NO-treated and un-
treated groups in mortality, need for
ECMO, or oxygenation.
The incidence of disturbances of
the central nervous system (convul-
sions or hemorrhagic disorders) and
development of chronic pulmonary
disease during hospitalization were the
same for the NO-treated group and the
control group, regardless of whether
the PPHN was or was not associated
with CDH or pulmonary hypoplasia.
RESUMO RHCFAP/3017
OLIVEIRA CAC e col. - Avaliação do
uso do óxido nítrico no tratamento
da hipertensão pulmonar persis-
tente do recém-nascido: uma
metanálise. Rev. Hosp. Clín. Fac.
Med. S. Paulo 55 (4):145-154,
2000.
Objetivos: Avaliar o papel do óxi-
do nítrico inalatório no tratamento da
hipertensão pulmonar persistente do
recém-nascido. Material e método:
Busca bibliográfica informatizada para
janeiro de 1990 a março de 1998
(MEDLINE, CURRENT CONTENTS
e LILACS) complementada manual-
mente. Apenas ensaios clínicos contro-
lados e randomizados foram seleciona-
dos. Intervenção: tratamento com óxi-
do nítrico inalatório comparado com
tratamento convencional. Desfechos:
morte, necessidade de ECMO,
oxigenação sistêmica, complicações
em sistema nervoso central e doença
pulmonar crônica. Qualidade metodo-
lógica: critério de escores, sendo treze
a pontuação máxima. Resultados: Nos
não portadores de hérnia diafragmática
o óxido nítrico inalatório não reduziu
a mortalidade, OR: 1,04 (IC 95%: 0,59
a 1,82), mas diminuiu a necessidade de
indicação de ECMO, RR: 0,73 (IC
95%: 0,6 a 0,9) e melhorou a oxi-
genação sistêmica, diferença média
ponderada (DMP) para PaO2 em 30 e
60min: 53,18 (IC 95%: 44,8 a 61,4) e
DMP para IO em 30 e 60min: -12,17
(IC 95%: -14,4 a -9,9). Nos portado-
res de hérnia diafragmática, não hou-
ve melhora da oxigenação arterial, nem
redução da mortalidade ou da necessi-
dade de ECMO, RR: 1,17 (IC 95%:
0,97 a 1,41). A incidência de compli-
cações neurológicas e de doença pul-
monar foram semelhantes para os dois
grupos.
DESCRITORES:  Oxido nítrico.
Recém nascido.  Hipertensão pulmo-
nar. ECMO. Metanálise.
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